• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过噬菌体肽展示技术鉴定出的高亲和力尿激酶受体拮抗剂。

High-affinity urokinase receptor antagonists identified with bacteriophage peptide display.

作者信息

Goodson R J, Doyle M V, Kaufman S E, Rosenberg S

机构信息

Chiron Corporation, Emeryville, CA 94608.

出版信息

Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7129-33. doi: 10.1073/pnas.91.15.7129.

DOI:10.1073/pnas.91.15.7129
PMID:8041758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC44352/
Abstract

Affinity selection of a 15-mer random peptide library displayed on bacteriophage M13 has been used to identify potent ligands for the human urokinase receptor, a key mediator of tumor cell invasion. A family of receptor binding bacteriophage ligands was obtained by sequentially and alternately selecting the peptide library on COS-7 monkey kidney cells and baculovirus-infected Sf9 insect cells overexpressing the human urokinase receptor. Nineteen peptides encoded by the random DNA regions of the selected bacteriophage were synthesized and tested in a urokinase receptor binding assay, where they competed with the labeled N-terminal fragment of urokinase with IC50 values ranging from 10 nM to 10 microM. All of the isolated peptides were linear and showed two relatively short conserved subsequences: LWXXAr (Ar = Y, W, F, or H) and XFXXYLW, neither of which is found in urokinase or its receptor. Competition experiments demonstrated that the most potent peptide, clone 20, prevented binding of bacteriophage displaying the urokinase receptor binding sequence (urokinase residues 13-32). In addition, this peptide blocked other apparently unrelated receptor binding bacteriophage, suggesting overlapping receptor interaction sites for all of these sequences. These results provide a demonstration of bacteriophage display identifying peptide ligands for a receptor expressed on cells and yield leads for the development of urokinase receptor antagonists.

摘要

利用展示在噬菌体M13上的15聚体随机肽库进行亲和选择,以鉴定人尿激酶受体的有效配体,人尿激酶受体是肿瘤细胞侵袭的关键介质。通过在COS-7猴肾细胞和过表达人尿激酶受体的杆状病毒感染的Sf9昆虫细胞上依次交替选择肽库,获得了一系列受体结合噬菌体配体。合成了所选噬菌体随机DNA区域编码的19种肽,并在尿激酶受体结合试验中进行测试,在该试验中它们与标记的尿激酶N端片段竞争,IC50值范围为10 nM至10 μM。所有分离的肽都是线性的,并且显示出两个相对较短的保守子序列:LWXXAr(Ar = Y、W、F或H)和XFXXYLW,在尿激酶或其受体中均未发现。竞争实验表明,最有效的肽克隆20可阻止展示尿激酶受体结合序列(尿激酶残基13 - 32)的噬菌体的结合。此外,该肽还可阻断其他明显不相关的受体结合噬菌体,表明所有这些序列具有重叠的受体相互作用位点。这些结果证明了噬菌体展示可鉴定细胞上表达的受体的肽配体,并为尿激酶受体拮抗剂的开发提供了线索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89ad/44352/3c02ce7a35ec/pnas01137-0426-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89ad/44352/3c02ce7a35ec/pnas01137-0426-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89ad/44352/3c02ce7a35ec/pnas01137-0426-a.jpg

相似文献

1
High-affinity urokinase receptor antagonists identified with bacteriophage peptide display.通过噬菌体肽展示技术鉴定出的高亲和力尿激酶受体拮抗剂。
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7129-33. doi: 10.1073/pnas.91.15.7129.
2
Random peptide bacteriophage display as a probe for urokinase receptor ligands.随机肽噬菌体展示作为尿激酶受体配体的探针
Biol Chem. 2002 Jan;383(1):149-58. doi: 10.1515/BC.2002.015.
3
Yeast expression and phagemid display of the human urokinase plasminogen activator epidermal growth factor-like domain.
Protein Eng. 1995 May;8(5):463-70. doi: 10.1093/protein/8.5.463.
4
Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.使用十肽拮抗剂对人尿激酶型纤溶酶原激活剂受体进行光亲和标记。复合配体结合位点和短结构域间间隔的证据。
Biochemistry. 1998 Mar 17;37(11):3612-22. doi: 10.1021/bi972787k.
5
Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species.尿激酶及肽拮抗剂与尿激酶受体的差异性结合:来自四种灵长类动物受体特性研究的证据
Biol Chem. 2001 Mar;382(3):435-42. doi: 10.1515/BC.2001.053.
6
Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.人尿激酶型纤溶酶原激活剂氨基末端片段与U937单核细胞上特定受体的分化增强结合。
Proc Natl Acad Sci U S A. 1985 Aug;82(15):4939-43. doi: 10.1073/pnas.82.15.4939.
7
One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.利用组合化学开发的合成肽一步亲和纯化重组尿激酶型纤溶酶原激活剂受体。
Protein Expr Purif. 2007 Apr;52(2):286-96. doi: 10.1016/j.pep.2006.08.011. Epub 2006 Aug 30.
8
Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.通过对尿激酶型纤溶酶原激活剂受体进行光亲和标记来鉴定参与配体结合的特定位点。位于uPAR结构域I和III中同等位置的残基参与复合配体结合位点的组装。
Biochemistry. 1998 Nov 24;37(47):16494-505. doi: 10.1021/bi981203r.
9
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).环[19,31][D-半胱氨酸19]-尿激酶型纤溶酶原激活剂19-31是尿激酶型纤溶酶原激活剂与其受体(CD87)相互作用的强效竞争性拮抗剂。
Biol Chem. 2001 Aug;382(8):1197-205. doi: 10.1515/BC.2001.150.
10
Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry.通过酰胺氢交换和质谱研究尿激酶受体与肽拮抗剂相互作用的动力学。
Biochemistry. 2004 Nov 30;43(47):15044-57. doi: 10.1021/bi048706j.

引用本文的文献

1
Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.用环 AE105 变体在体内靶向成像 uPAR 表达。
Sci Rep. 2023 Oct 11;13(1):17248. doi: 10.1038/s41598-023-43934-w.
2
Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention.以非侵入性成像和治疗干预为目的,针对人类疾病中的尿激酶型纤溶酶原激活物受体(uPAR)
Front Cell Dev Biol. 2021 Aug 20;9:732015. doi: 10.3389/fcell.2021.732015. eCollection 2021.
3
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer.

本文引用的文献

1
Design of synthetic gene libraries encoding random sequence proteins with desired ensemble characteristics.编码具有所需整体特征的随机序列蛋白质的合成基因文库设计。
Protein Sci. 1993 Aug;2(8):1249-54. doi: 10.1002/pro.5560020807.
2
Characterization of ligand binding to immobilized biotinylated extracellular domains of three growth factor receptors.
Anal Biochem. 1993 Jun;211(2):261-6. doi: 10.1006/abio.1993.1267.
3
Prevention of metastasis by inhibition of the urokinase receptor.通过抑制尿激酶受体预防转移。
尿激酶型纤溶酶原激活物受体的分子成像:癌症之外的机遇
EJNMMI Res. 2020 Jul 28;10(1):87. doi: 10.1186/s13550-020-00673-7.
4
Therapeutics targeting the fibrinolytic system.靶向纤维蛋白溶解系统的治疗方法。
Exp Mol Med. 2020 Mar;52(3):367-379. doi: 10.1038/s12276-020-0397-x. Epub 2020 Mar 9.
5
Phage display screening of therapeutic peptide for cancer targeting and therapy.噬菌体展示技术筛选用于癌症靶向治疗的治疗性肽。
Protein Cell. 2019 Nov;10(11):787-807. doi: 10.1007/s13238-019-0639-7. Epub 2019 May 28.
6
upconverting/downshifting luminescent detection of tumor markers based on Eu-activated core-shell-shell lanthanide nanoprobes.基于铕激活的核壳壳层镧系纳米探针的肿瘤标志物上转换/下转换发光检测
Chem Sci. 2016 Aug 1;7(8):5013-5019. doi: 10.1039/c6sc01195k. Epub 2016 May 12.
7
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.尿激酶型纤溶酶原激活剂(uPA)及其受体(uPAR)的多方面作用:诊断、预后及治疗应用
Front Oncol. 2018 Feb 12;8:24. doi: 10.3389/fonc.2018.00024. eCollection 2018.
8
Systems approaches to design of targeted therapeutic delivery.靶向治疗递送设计的系统方法。
Wiley Interdiscip Rev Syst Biol Med. 2015 Sep-Oct;7(5):253-65. doi: 10.1002/wsbm.1304. Epub 2015 May 6.
9
Combinatorial peptide libraries: mining for cell-binding peptides.组合肽库:筛选细胞结合肽
Chem Rev. 2014 Jan 22;114(2):1020-81. doi: 10.1021/cr400166n. Epub 2013 Dec 3.
10
Synthesis and Biological Activity of -Sulfonyltripeptides with C-Terminal Arginine as Potential Serine Proteases Inhibitors.以C端精氨酸为潜在丝氨酸蛋白酶抑制剂的磺酰基三肽的合成及生物活性
Int J Pept Res Ther. 2013;19(3):191-198. doi: 10.1007/s10989-012-9338-4. Epub 2012 Dec 2.
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5021-5. doi: 10.1073/pnas.90.11.5021.
4
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.尿激酶受体存在于乳腺导管癌的肿瘤相关巨噬细胞中。
Cancer Res. 1993 Apr 15;53(8):1911-5.
5
The N-terminal domain of human urokinase receptor contains two distinct regions critical for ligand recognition.
Blood. 1993 Nov 1;82(9):2719-29.
6
Human antibody fragments specific for human blood group antigens from a phage display library.来自噬菌体展示文库的针对人类血型抗原的人源抗体片段。
Biotechnology (N Y). 1993 Oct;11(10):1145-9. doi: 10.1038/nbt1093-1145.
7
Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library.从噬菌体展示文库中筛选与α5β1整合素结合的肽段。
J Biol Chem. 1993 Sep 25;268(27):20205-10.
8
Ligand: a versatile computerized approach for characterization of ligand-binding systems.配体:一种用于表征配体结合系统的通用计算机化方法。
Anal Biochem. 1980 Sep 1;107(1):220-39. doi: 10.1016/0003-2697(80)90515-1.
9
Cell-associated plasminogen activation: regulation and physiological functions.
Annu Rev Cell Biol. 1988;4:93-126. doi: 10.1146/annurev.cb.04.110188.000521.
10
The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.尿激酶的受体结合序列。蛋白酶生长因子模块的生物学功能。
J Biol Chem. 1987 Apr 5;262(10):4437-40.